Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

ix month periods ended January 31, 2008, compared to $310,000 and $600,000, respectively, for the same periods last year. Margins, on percentage basis, have remained relatively stable in both the three and six month periods ended January 31, 2008, when compared to 2007.

Research & development

Research & development costs for the three and six month periods ended January 31, 2008, totaled $1,029,000 and $1,811,000, respectively, compared to $1,065,000 and $1,973,000, respectively, a year ago. In the three and six month periods ended January 31, 2008, research & development expenditures for both L-DOS47 and Topical Interferon Alpha2-b were less than in the same periods a year ago, with the majority of the lower research and development expenditures related to L-DOS47.

The reduction in research and development expenditures for L-DOS47 in the period were related to the various stages of completion associated with the multiple projects within the L-DOS47 program. Helix intends to seek approval in 2008 from the U.S. Food and Drug Administration ("FDA") for a Phase I clinical study in lung adenocarcinoma patients and, therefore, is currently advancing its L-DOS47 scale-up manufacturing program in anticipation of furnishing product for the clinical trial.

Research and development expenditures related to the Phase II trial in Sweden for ano-genital warts ("AGW") were more than offset by the reduction in costs associated with the Phase II study in Germany for women with precancerous, HPV induced low-grade cervical lesions.

The late-stage Phase II study in Germany was completed during the six month period ended January 31, 2007. Based on the positive findings, the Company is currently developing plans for a large, randomized, placebo-controlled double-blind study to evaluate the product in an expanded patient population in addition to preparatory work in anticipation of Investigational New Drug ("IND") and Clinical Trial Application ("CTA") f
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
(Date:7/29/2015)... 29, 2015  HealthSouth Corporation (NYSE: ... of post-acute healthcare services, offering both facility-based and ... operations for the second quarter ended June 30, 2015. ... by strong volume growth in both segments and ... Jay Grinney, President and Chief Executive Officer of ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17
... MOUNTAIN VIEW, Calif., Dec. 4 Based on ... & Sullivan recognizes Honeywell Enraf with the 2008 ... Honeywell Enraf,s comprehensive suite of blending products facilitates ... and other materials, but also minimizes the end-products, ...
... of Life Technologies Corporation (NASDAQ:LIFE), a provider of ... announced that its technology for next-generation genomic analysis, ... Science Innovation of the Year for 2008 by ... the life science industry. In making the announcement ...
... an estimated ten percent of pregnant women in the U.S. ... cigarette byproducts from mothers who smoke affects an estimated 420,000 ... , Now, in the first study of its kind, a ... umbilical cord blood to better understand the fetal health risks ...
Cached Biology Technology:Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support 2Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... has released the final "Integrated Science Assessment for Oxides ... of the scientific literature on the potential adverse human ... particularly nitrogen dioxide or NO2. There are significant ... scientific review document released in 1993. Oxides ...
... in Spanish . Cancer is a ... adaptative changes give higher proliferative capacity to cancer cells, ... agents. The research group led by Dr. Jos Carlos ... the CSIC (IIBB-CSIC), a centre linked to the Institut ...
... IMMEDIATE RELEASE Detecting flu viruses in remote areas of ... Researchers in Ohio and New Mexico are reporting an advance ... viruses one that requires no refrigeration and can be used ... emerge. Their new method, the first to use sugar molecules rather ...
Cached Biology News:Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer 2American Chemical Society's Weekly PressPac -- July 9, 2008 2American Chemical Society's Weekly PressPac -- July 9, 2008 3American Chemical Society's Weekly PressPac -- July 9, 2008 4American Chemical Society's Weekly PressPac -- July 9, 2008 5American Chemical Society's Weekly PressPac -- July 9, 2008 6American Chemical Society's Weekly PressPac -- July 9, 2008 7American Chemical Society's Weekly PressPac -- July 9, 2008 8American Chemical Society's Weekly PressPac -- July 9, 2008 9
Ready-to-use solution....
...
... Conjugated peptides or recombinant proteins ... to produce antibodies in 2 rabbits. pre-immune ... ELISA test until the titer reaches 1:4,000 ... Protein G purification Antibodies are eluted ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: